*Recent trial suggested that Jakafi in combination with Xeloda may be useful in second line therapy against pancreatic cancer particularly those induced or accompanied by strong inflammatory response as suggested by high lebel of CRP (C-reative protein) (Targeted Therapy).
*With over 20% success in patents with NSCL cancers, Nivolumab /Pembrolizumab and other anti PD-1/PD-L1 continue to impress researchers and are bound to change the therapeutic approaches in this disease. Soon everyone will be screened for these antigens as response rates seem to correlate with their presence.
*Does inhibiting Cytokines inducing cachexia in cancer able to change overall survival rates in cancers. What is the relationships between these Cytokines and Mitochondrial changes and telomeres?
No comments:
Post a Comment